GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » LT-Debt-to-Total-Asset

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) LT-Debt-to-Total-Asset : 0.20 (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zhejiang Huahai Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.20.

Zhejiang Huahai Pharmaceutical Co's long-term debt to total assets ratio declined from Mar. 2023 (0.26) to Mar. 2024 (0.20). It may suggest that Zhejiang Huahai Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Zhejiang Huahai Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Zhejiang Huahai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.23 0.23 0.26 0.22

Zhejiang Huahai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.24 0.25 0.22 0.20

Zhejiang Huahai Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Zhejiang Huahai Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=4067.133/18599.97
=0.22

Zhejiang Huahai Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=4042.814/20089.317
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Huahai Pharmaceutical Co  (SHSE:600521) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zhejiang Huahai Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
SHSE:600518 SHSE:600329 SHSE:600380 SZSE:002262 SHSE:600062 SHSE:603707 SZSE:300142 SHSE:600535 SHSE:600129 SZSE:002773 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024
Website
http://www.huahaipharm.com
Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.
Executives
Chen Bao Hua Director
Shang Fei senior management
Du Jun Director
Su Yan Director
Chen Dun Yuan senior management
Li Hong Director
Guo Si Jia senior management
Li Min senior management
Xu Bo senior management
Wang Jie senior management
Chen Qi Mao senior management
Zhang Hong senior management
Zhang Mei senior management
Zhu Yong Hua Directors, senior managers
Wang Yi Hua senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines